Advanced search
Publication Cover
Pharmacogenomics Volume 11, 2010 - Issue 6
Submit an article Journal homepage
704
Views
3
CrossRef citations to date
0
Altmetric
Review

Drug Transporter Pharmacogenetics in Nucleoside-Based Therapies

Ekaitz Errasti-Murugarren1 The Department of Biochemistry and Molecular Biology, Institute of Biomedicine, University of Barcelona, Diagonal 645, 08028Barcelona, Spain;2 Center for Biomedical Research Network in the Subject Area of Liver and Digestive Diseases (CIBERehd), Barcelona08071, SpainView further author information
&
Marçal Pastor-Anglada1 The Department of Biochemistry and Molecular Biology, Institute of Biomedicine, University of Barcelona, Diagonal 645, 08028Barcelona, Spain;2 Center for Biomedical Research Network in the Subject Area of Liver and Digestive Diseases (CIBERehd), Barcelona08071, SpainCorrespondence[email protected]
View further author information
Pages 809-841 | Published online: 27 May 2010

Bibliography

  • Anderle P , HuangY, SadeeW: Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays.Eur. J. Pharm. Sci.21(1) , 17–24 (2004).
  • Pastor-Anglada M , Cano-SoldadoP, Molina-ArcasM et al.: Cell entry and export of nucleoside analogues.Virus Res.107(2) , 151–164 (2005).
  • Pastor-Anglada M , Cano-SoldadoP, Errasti-MurugarrenE, CasadoFJ: SLC28 genes and concentrative nucleoside transporter (CNT) proteins.Xenobiotica38(7–8) , 972–994 (2008).
  • Young JD , YaoSY, SunL, CassCE, BaldwinSA: Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins.Xenobiotica38(7–8) , 995–1021 (2008).
  • Mackey JR , YaoSY, SmithKM et al.: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.J. Natl Cancer Inst.91(21) , 1876–1881 (1999).
  • Mata JF , Garcia-ManteigaJM, LostaoMP et al.: Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.Mol. Pharmacol.59(6) , 1542–1548 (2001).
  • Cano-Soldado P , LorrayozIM, Molina-ArcasM et al.: Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1).Antivir. Ther.9(6) , 993–1002 (2004).
  • Lang TT , SelnerM, YoungJD, CassCE: Acquisition of human concentrative nucleoside transporter 2 (HCNT2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells.Mol. Pharmacol.60(5) , 1143–1152 (2001).
  • Errasti-Murugarren E , Pastor-AngladaM, CasadoFJ: Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs.J. Physiol.582(Pt 3) , 1249–1260 (2007).
  • Ritzel MW , NgAM, YaoSY et al.: Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system CIB).J. Biol. Chem.276(4) , 2914–2927 (2001).
  • Naito T , TokashikiS, MinoY et al.: Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients.Basic Clin. Pharmacol. Toxicol.106(4) , 310–316 (2009).
  • Osses N , PearsonJD, YudilevichDL, JarvisSM: Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter.Biochem. J.317(Pt 3) , 843–848 (1996).
  • Crawford CR , PatelDH, NaeveC, BeltJA: Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter EI by functional expression in a transport-deficient cell line.J. Biol. Chem.273(9) , 5288–5293 (1998).
  • Mani RS , HammondJR, MarjanJM et al.: Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes.J. Biol. Chem.273(46) , 30818–30825 (1998).
  • Lai Y , TseCM, UnadkatJD: Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs.J. Biol. Chem.279(6) , 4490–4497 (2004).
  • Baldwin SA , YaoSY, HydeRJ et al.: Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes.J. Biol. Chem.280(16) , 15880–15887 (2005).
  • Govindarajan R , LeungGP, ZhouM, TseCM, WangJ, UnadkatJD: Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3.Am. J. Physiol. Gastrointest. Liver Physiol.296(4) , G910–G922 (2009).
  • Scruggs ER , Dirks Naylor AJ: Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology82(2) , 83–88 (2008).
  • Zhou M , XiaL, EngelK, WangJ: Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family.J. Biol. Chem.282(5) , 3188–3195 (2007).
  • Li H , SmolenGA, BeersLF et al.: Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor.PLoS One3(6) , E2353 (2008).
  • Ciarimboli G : Organic cation transporters.Xenobiotica38(7–8) , 936–971 (2008).
  • Srimaroeng C , PerryJL, PritchardJB: Physiology, structure, and regulation of the cloned organic anion transporters.Xenobiotica38(7–8) , 889–935 (2008).
  • Hu H , EndresCJ, ChangC et al.: Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3).Mol. Pharmacol.69(5) , 1542–1553 (2006).
  • Fotoohi AK , LindqvistM, PetersonC, AlbertioniF: Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.Biochem. Biophys. Res. Commun.343(1) , 208–215 (2006).
  • Minuesa G , VolkC, Molina-ArcasM et al.: Transport of lamivudine [(-)-β-l-2´,3´-dideoxy-3´-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.J. Pharmacol. Exp. Ther.329(1) , 252–261 (2009).
  • Takeda M , KhamdangS, NarikawaS et al.: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.J. Pharmacol. Exp. Ther.300(3) , 918–924 (2002).
  • Tzvetkov MV , VormfeldeSV, BalenD et al.: The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.Clin. Pharmacol. Ther.86(3) , 299–306 (2009).
  • Song IS , ShinHJ, ShimEJ et al.: Genetic variants of the organic cation transporter 2 influence the disposition of metformin.Clin. Pharmacol. Ther.84(5) , 559–562 (2008).
  • Vanwert AL , GionfriddoMR, SweetDH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology.Biopharm. Drug Dispos.31(1) , 1–71 (2010).
  • Kobayashi Y , OhshiroN, TsuchiyaA, KohyamaN, OhbayashiM, YamamotoT: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOAT3): further substrate specificity of mOAT3.Drug Metab. Dispos.32(5) , 479–483 (2004).
  • Kobayashi Y , OhshiroN, SakaiR, OhbayashiM, KohyamaN, YamamotoT: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOAT2 [SLC22A7]).J. Pharm. Pharmacol.57(5) , 573–578 (2005).
  • Rubio-Aliaga I , DanielH: Peptide transporters and their roles in physiological processes and drug disposition.Xenobiotica38(7–8) , 1022–1042 (2008).
  • Ganapathy ME , HuangW, WangH, GanapathyV, LeibachFH: Valacyclovir: a substrate for the intestinal and renal peptide transporters PepT1 and PepT2.Biochem. Biophys. Res. Commun.246(2) , 470–475 (1998).
  • Thomsen AE , ChristensenMS, BaggerMA, SteffansenB: Acyclovir prodrug for the intestinal di/tri-peptide transporter PepT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells.Eur. J. Pharm. Sci.23(4–5) , 319–325 (2004).
  • Landowski CP , SongX, LorenziPL, HilfingerJM, AmidonGL: Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.Pharm. Res.22(9) , 1510–1518 (2005).
  • Zhou SF : Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.Xenobiotica38(7–8) , 802–832 (2008).
  • Zhou SF , WangLL, DiYM et al.: Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.Curr. Med. Chem.15(20) , 1981–2039 (2008).
  • Loo TW , ClarkeDM: Mutational analysis of ABC proteins.Arch. Biochem. Biophys.476(1) , 51–64 (2008).
  • Weiss J , TheileD, Ketabi-KiyanvashN, LindenmaierH, HaefeliWE: Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.Drug Metab. Dispos.35(3) , 340–344 (2007).
  • Walsh N , LarkinA, KennedyS et al.: Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.BMC Urol.9 , 6 (2009).
  • Nagashige M , UshigomeF, KoyabuN et al.: Basal membrane localization of MRP1 in human placental trophoblast.Placenta24(10) , 951–958 (2003).
  • Servais A , LechatP, ZahrN et al.: [Tubular transporters OAT1 and MRP2 and clearance of adefovir].Nephrol. Ther.1(5) , 296–300 (2005).
  • Cundy KC : Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.Clin. Pharmacokinet.36(2) , 127–143 (1999).
  • Rius M , NiesAT, Hummel-EisenbeissJ, JedlitschkyG, KepplerD: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.Hepatology38(2) , 374–384 (2003).
  • Lee K , Klein-SzantoAJ, KruhGD: Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.J. Natl Cancer Inst.92(23) , 1934–1940 (2000).
  • Van Aubel RA , SmeetsPH, PetersJG, BindelsRJ, RusselFG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.J. Am. Soc. Nephrol.13(3) , 595–603 (2002).
  • Meyer Zu Schwabedissen HE , GrubeM, HeydrichB et al.: Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation.Am. J. Pathol.166(1) , 39–48 (2005).
  • Hopper-Borge E , XuX, ShenT, ShiZ, ChenZS, KruhGD: Human multidrug resistance protein 7 (ABCC1 0) is a resistance factor for nucleoside analogues and epothilone B.Cancer Res.69(1) , 178–184 (2009).
  • Robey RW , ToKK, PolgarO et al.: ABCG2: a perspective.Adv. Drug Deliv. Rev.61(1) , 3–13 (2009).
  • Gradhand U , KimRB: Pharmacogenomics of MRP transporters (ABCC1 –5) and BCRP (ABCG2).Drug Metab. Rev.40(2) , 317–354 (2008).
  • Heinemann V , HertelLW, GrindeyGB, PlunkettW: Comparison of the cellular pharmacokinetics and toxicity of 2´,2´-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine.Cancer Res.48(14) , 4024–4031 (1988).
  • Abbruzzese JL , GrunewaldR, WeeksEA et al.: A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine.J. Clin. Oncol.9(3) , 491–498 (1991).
  • Molina-Arcas M , MarceS, VillamorN et al.: Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.Leukemia19(1) , 64–68 (2005).
  • Dresser MJ , LeabmanMK, GiacominiKM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters.J. Pharm. Sci.90(4) , 397–421 (2001).
  • Zair ZM , ElorantaJJ, StiegerB, Kullak-UblickGA: Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PepT (SLC15) transporters in the intestine, liver and kidney.Pharmacogenomics9(5) , 597–624 (2008).
  • Wada M : Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.Cancer Lett.234(1) , 40–50 (2006).
  • Molho-Pessach V , LererI, AbeliovichD et al.: The H syndrome is caused by mutations in the nucleoside transporter hENT3.Am. J. Hum. Genet.83(4) , 529–534 (2008).
  • Lazar A , WalitzaS, JetterA et al.: Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder.Int. J. Neuropsychopharmacol.11(1) , 35–48 (2008).
  • Gray JH , MangraviteLM, OwenRP et al.: Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations.Mol. Pharmacol.65(3) , 512–519 (2004).
  • Soo RA , WangLZ, NgSS et al.: Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Lung Cancer63(1) , 121–127 (2009).
  • Owen RP , GrayJH, TaylorTR et al.: Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2.Pharmacogenet. Genomics15(2) , 83–90 (2005).
  • Li L , TanCM, KooSH, ChongKT, LeeEJ: Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians.Pharmacogenet. Genomics17(9) , 783–786 (2007).
  • Li L , KooSH, HongIH, LeeEJ: Identification of functional promoter haplotypes of human concentrative nucleoside transporter 2, hCNT2 (SLC28A2).Drug Metab. Pharmacokinet.24(2) , 161–166 (2009).
  • Yee SW , ShimaJE, HesselsonS et al.: Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).J. Pharmacol. Exp. Ther.328(3) , 699–707 (2009).
  • Badagnani I , ChanW, CastroRA et al.: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).Pharmacogenomics J.5(3) , 157–165 (2005).
  • Damaraju S , ZhangJ, VisserF et al.: Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene.Pharmacogenet. Genomics15(3) , 173–182 (2005).
  • Errasti-Murugarren E , Cano-SoldadoP, Pastor-AngladaM, CasadoFJ: Functional characterization of a nucleoside-derived drug transporter variant (hCNT3c602r) showing altered sodium-binding capacity.Mol. Pharmacol.73(2) , 379–386 (2008).
  • Myers SN , GoyalRK, RoyJD, FairfullLD, WilsonJW, FerrellRE: Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.Pharmacogenet. Genomics16(5) , 315–320 (2006).
  • Owen RP , LagpacanLL, TaylorTR et al.: Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2.Drug Metab. Dispos.34(1) , 12–15 (2006).
  • Cliffe ST , KramerJM, HussainK et al.: SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway.Hum. Mol. Genet.18(12) , 2257–2265 (2009).
  • Shu Y , LeabmanMK, FengB et al.: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.Proc. Natl Acad. Sci. USA100(10) , 5902–5907 (2003).
  • Shu Y , SheardownSA, BrownC et al.: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.J. Clin. Invest117(5) , 1422–1431 (2007).
  • Kerb R , BrinkmannU, ChatskaiaN et al.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.Pharmacogenetics12(8) , 591–595 (2002).
  • Song IS , ShinHJ, ShinJG: Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.Xenobiotica38(9) , 1252–1262 (2008).
  • Leabman MK , HuangCC, KawamotoM et al.: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.Pharmacogenetics12(5) , 395–405 (2002).
  • Ogasawara K , TeradaT, MotohashiH et al.: Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.J. Hum. Genet.53(7) , 607–614 (2008).
  • Nies AT , KoepsellH, WinterS et al.: Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.Hepatology50(4) , 1227–1240 (2009).
  • Bleasby K , HallLA, PerryJL, MohrenweiserHW, PritchardJB: Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).J. Pharmacol. Exp. Ther.314(2) , 923–931 (2005).
  • Fujita T , BrownC, CarlsonEJ et al.: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).Pharmacogenet. Genomics15(4) , 201–209 (2005).
  • Erdman AR , MangraviteLM, UrbanTJ et al.: The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics.Am. J. Physiol. Renal Physiol.290(4) , F905–F912 (2006).
  • Anderle P , NielsenCU, PinsonneaultJ, KrogPL, BrodinB, SadeeW: Genetic variants of the human dipeptide transporter PepT1.J. Pharmacol. Exp. Ther.316(2) , 636–646 (2006).
  • Zucchelli M , TorkvistL, BressoF et al.: PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease.Inflamm. Bowel Dis.15(10) , 1562–1569 (2009).
  • Zhang EY , FuDJ, PakYA et al.: Genetic polymorphisms in human proton-dependent dipeptide transporter PepT1: implications for the functional role of pro586.J. Pharmacol. Exp. Ther.310(2) , 437–445 (2004).
  • Gervasini G , CarrilloJA, GarciaM, San Jose C, Cabanillas A, Benitez J: Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677 T/A gene polymorphism is associated with high risk of lung cancer. Cancer107(12) , 2850–2857 (2006).
  • Swerts K , De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J: Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur. J. Cancer42(3) , 295–309 (2006).
  • Mendoza JL , UrcelayE, LanaR et al.: MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn‘s disease.Inflamm. Bowel Dis.13(5) , 585–590 (2007).
  • Kim RB , LeakeBF, ChooEF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans.Clin. Pharmacol. Ther.70(2) , 189–199 (2001).
  • Kimchi-Sarfaty C , GribarJJ, GottesmanMM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.Mol. Pharmacol.62(1) , 1–6 (2002).
  • Salama NN , YangZ, BuiT, HoRJ: MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells.J. Pharm. Sci.95(10) , 2293–2308 (2006).
  • Hoffmeyer S , BurkO, Von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7) , 3473–3478 (2000).
  • Nakamura T , SakaedaT, HorinouchiM et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy japanese subjects.Clin. Pharmacol. Ther.71(4) , 297–303 (2002).
  • Goto M , MasudaS, SaitoH et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.Pharmacogenetics12(6) , 451–457 (2002).
  • Turgut S , YarenA, KursunluogluR, TurgutG: MDR1 C3435T polymorphism in patients with breast cancer.Arch. Med. Res.38(5) , 539–544 (2007).
  • George J , DharanipragadaK, KrishnamachariS, ChandrasekaranA, SamSS, SunderE: A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.Clin. Breast Cancer9(3) , 161–165 (2009).
  • Siegsmund M , BrinkmannU, SchaffelerE et al.: Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors.J. Am. Soc. Nephrol.13(7) , 1847–1854 (2002).
  • Jamroziak K , MlynarskiW, BalcerczakE et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia.Eur. J. Haematol.72(5) , 314–321 (2004).
  • Farnood A , NaderiN, MoghaddamSJ et al.: The frequency of C3435T MDR1 gene polymorphism in iranian patients with ulcerative colitis.Int. J. Colorectal Dis.22(9) , 999–1003 (2007).
  • Woodahl EL , CrouthamelMH, BuiT, ShenDD, HoRJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents.Cancer Chemother. Pharmacol.64(1) , 183–188 (2009).
  • Tanabe M , IeiriI, NagataN et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.J. Pharmacol. Exp. Ther.297(3) , 1137–1143 (2001).
  • Conrad S , KauffmannHM, ItoK et al.: A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance.Pharmacogenetics12(4) , 321–330 (2002).
  • Letourneau IJ , DeeleyRG, ColeSP: Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1).Pharmacogenet. Genomics15(9) , 647–657 (2005).
  • Wang Z , WangB, TangK, LeeEJ, ChongSS, LeeCG: A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection.Hum. Mol. Genet.14(14) , 2075–2087 (2005).
  • Hulot JS , VillardE, MaguyA et al.: A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination.Pharmacogenet. Genomics15(5) , 277–285 (2005).
  • Izzedine H , HulotJS, VillardE et al.: Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.J. Infect Dis.194(11) , 1481–1491 (2006).
  • Meyer Zu Schwabedissen HE , JedlitschkyG, GratzM et al.: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation.Drug Metab. Dispos.33(7) , 896–904 (2005).
  • Giessmann T , ModessC, HeckerU et al.: CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.Clin. Pharmacol. Ther.75(3) , 213–222 (2004).
  • Lang T , HitzlM, BurkO et al.: Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver.Pharmacogenetics14(3) , 155–164 (2004).
  • Kobayashi K , ItoK, TakadaT, SugiyamaY, SuzukiH: Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3.Pharmacogenet. Genomics18(9) , 823–833 (2008).
  • Fukushima-Uesaka H , SaitoY, MaekawaK et al.: Genetic variations of the ABC transporter gene ABCC3 in a Japanese population.Drug Metab. Pharmacokinet.22(2) , 129–135 (2007).
  • Müller P , AsherN, HeledM, CohenSB, RischA, RundD: Polymorphisms in transporter and Phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.Leuk. Res.32(6) , 919–929 (2008).
  • Abla N , ChinnLW, NakamuraT et al.: The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.J. Pharmacol. Exp. Ther.325(3) , 859–868 (2008).
  • Janke D , MehralivandS, StrandD et al.: 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.Hum. Mutat29(5) , 659–669 (2008).
  • Krishnamurthy P , SchwabM, TakenakaK et al.: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.Cancer Res.68(13) , 4983–4989 (2008).
  • Kiser JJ , AquilanteCL, AndersonPL, KingTM, CartenML, FletcherCV: Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.J. Acquir. Immune Defic. Syndr.47(3) , 298–303 (2008).
  • Anderson PL , LambaJ, AquilanteCL, SchuetzE, FletcherCV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.J. Acquir. Immune Defic. Syndr.42(4) , 441–449 (2006).
  • Gradhand U , LangT, SchaeffelerE et al.: Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.Pharmacogenomics J.8(1) , 42–52 (2008).
  • Toyoda Y , SakuraiA, MitaniY et al.: Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type?FASEB J.23(6) , 2001–2013 (2009).
  • Tamura A , OnishiY, AnR et al.: In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.Drug Metab. Pharmacokinet.22(6) , 428–440 (2007).
  • Mizuarai S , AozasaN, KotaniH: Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2.Int. J. Cancer109(2) , 238–246 (2004).
  • Yanase K , TsukaharaS, MitsuhashiJ, SugimotoY: Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.Cancer Lett.234(1) , 73–80 (2006).
  • Furukawa T , WakabayashiK, TamuraA et al.: Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.Pharm. Res.26(2) , 469–479 (2009).
  • Tamura A , WatanabeM, SaitoH et al.: Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.Mol. Pharmacol.70(1) , 287–296 (2006).
  • Tamura A , WakabayashiK, OnishiY et al.: Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.Cancer Sci.98(2) , 231–239 (2007).
  • Sparreboom A , GelderblomH, MarshS et al.: Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.Clin. Pharmacol. Ther.76(1) , 38–44 (2004).
  • Sparreboom A , LoosWJ, BurgerH et al.: Effect of ABCG2 genotype on the oral bioavailability of topotecan.Cancer Biol. Ther.4(6) , 650–658 (2005).
  • Mey V , GiovannettiE, De Braud F et al.: In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br. J. Cancer95(3) , 289–297 (2006).
  • Marechal R , MackeyJR, LaiR et al.: Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.Clin. Cancer Res.15(8) , 2913–2919 (2009).
  • Marce S , Molina-ArcasM, VillamorN et al.: Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.Haematologica91(7) , 895–902 (2006).
  • Galmarini CM : Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samples.Haematologica91(7) , 866B (2006).
  • Giovannetti E , Del Tacca M, Mey V et al.: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res.66(7) , 3928–3935 (2006).
  • Farrell JJ , ElsalehH, GarciaM et al.: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.Gastroenterology136(1) , 187–195 (2009).
  • Spratlin J , SanghaR, GlubrechtD et al.: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.Clin. Cancer Res.10(20) , 6956–6961 (2004).
  • Santini D , PerroneG, VincenziB et al.: Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.Ann Oncol.19(4) , 724–728 (2008).
  • Stam RW , Den Boer ML, Meijerink JP et al.: Differential mRNA expression of ARA-C-metabolizing enzymes explains ARA-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood101(4) , 1270–1276 (2003).
  • Tsujie M , NakamoriS, NakahiraS et al.: Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.Anticancer Res.27(4B) , 2241–2249 (2007).
  • Gloeckner-Hofmann K , Guillen-GomezE, SchmidtgenC et al.: Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.Oncology70(3) , 238–244 (2006).
  • Rabascio C , LaszloD, AndreolaG et al.: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström‘s macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2´-deoxyadenosine (2-CDA) and rituximab.Leuk. Res.34(4) , 454–457 (2009).
  • Farre X , Guillen-GomezE, SanchezL et al.: Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.Int. J. Cancer112(6) , 959–966 (2004).
  • Oguri T , AchiwaH, MuramatsuH et al.: The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.Cancer Lett.256(1) , 112–119 (2007).
  • Hubeek I , StamRW, PetersGJ et al.: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.Br. J. Cancer93(12) , 1388–1394 (2005).
  • Wojtal KA , ElorantaJJ, HruzP et al.: Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients.Drug Metab. Dispos.37(9) , 1871–1877 (2009).
  • Bakhiya N , ArltVM, BahnA, BurckhardtG, PhillipsDH, GlattH: Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy.Toxicology264(1–2) , 74–79 (2009).
  • Andreadis C , GimottyPA, WahlP et al.: Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.Blood109(8) , 3409–3416 (2007).
  • Shi H , LuD, ShuY, ShiW, LuS, WangK: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.Cancer Invest26(4) , 344–351 (2008).
  • Kourti M , VavatsiN, GombakisN et al.: Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.Int. J. Hematol.86(2) , 166–173 (2007).
  • Huh HJ , ParkCJ, JangS et al.: Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia.J. Korean Med. Sci.21(2) , 253–258 (2006).
  • Noma B , SasakiT, FujimotoY et al.: Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.Int. J. Oncol.33(6) , 1187–1194 (2008).
  • Hinoshita E , UchiumiT, TaguchiK et al.: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.Clin. Cancer Res.6(6) , 2401–2407 (2000).
  • Nies AT , KonigJ, PfannschmidtM, KlarE, HofmannWJ, KepplerD: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma.Int. J. Cancer94(4) , 492–499 (2001).
  • Rost D , KonigJ, WeissG, KlarE, StremmelW, KepplerD: Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia.Gastroenterology121(5) , 1203–1208 (2001).
  • Konig J , HartelM, NiesAT et al.: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.Int. J. Cancer115(3) , 359–367 (2005).
  • Rau S , AutschbachF, RiedelHD et al.: Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.Eur. J. Clin. Invest38(2) , 134–142 (2008).
  • Norris MD , SmithJ, TanabeK et al.: Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.Mol. Cancer Ther.4(4) , 547–553 (2005).
  • Hagmann W , JesnowskiR, FaissnerR, GuoC, LohrJM: ATP-binding cassette c transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.Pancreatology9(1–2) , 136–144 (2009).
  • Steinbach D , GilletJP, SauerbreyA et al.: ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.Clin. Cancer Res.12(14 Pt 1) , 4357–4363 (2006).
  • Kim YH , IshiiG, GotoK et al.: Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.Lung Cancer65(1) , 105–111 (2009).
  • Englund G , JacobsonA, RorsmanF, ArturssonP, KindmarkA, RonnblomA: Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1).Inflamm. Bowel Dis.13(3) , 291–297 (2007).
  • Gutmann H , HruzP, ZimmermannC et al.: Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls.Digestion78(2–3) , 154–162 (2008).
  • Solbach TF , PaulusB, WeyandM, EschenhagenT, ZolkO, FrommMF: ATP-binding cassette transporters in human heart failure.Naunyn Schmiedebergs Arch. Pharmacol.377(3) , 231–243 (2008).
  • Aller SG , YuJ, WardA et al.: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.Science323(5922) , 1718–1722 (2009).
  • Saiko P , HorvathZ, JaegerW, SchottH, Fritzer-SzekeresM, SzekeresT: Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine – new drugs in cancer chemotherapy?In vivo19(1) , 205–214 (2005).
  • Wan L , CaoD, ZengJ, YanR, PizzornoG: Modulation of uridine phosphorylase gene expression by tumor necrosis factor-α enhances the antiproliferative activity of the capecitabine intermediate 5´-deoxy-5-fluorouridine in breast cancer cells.Mol. Pharmacol.69(4) , 1389–1395 (2006).
  • Tsuzuki M , HandaK, YamamotoK et al.: Chronic myeloid leukemia following chemotherapy with 5´-deoxy-5-fluorouridine for gastric cancer.Intern. Med.47(19) , 1739–1741 (2008).
  • Suehisa H , ToyookaS: Adjuvant chemotherapy for completely resected non-small-cell lung cancer.Acta Med. Okayama63(5) , 223–230 (2009).
  • Hillcoat BL , MccullochPB, FigueredoAT, EhsanMH, RosenfeldJM: Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.Br. J. Cancer38(6) , 719–724 (1978).
  • Wang WS , TzengCH, ChiouTJ et al.: High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin‘s lymphoma.Jpn. J. Clin. Oncol.27(3) , 154–157 (1997).
  • Wong A , SooRA, YongWP, InnocentiF: Clinical pharmacology and pharmacogenetics of gemcitabine.Drug Metab. Rev.41(2) , 77–88 (2009).
  • Ferrandina G , MeyV, NannizziS et al.: Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.Cancer Chemother. Pharmacol.65(4) , 679–686 (2010).
  • Sharma A , MohantiB, RainaV et al.: A Phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.Cancer Chemother. Pharmacol.65(3) , 497–502 (2010).
  • Garcia-Manero G : Demethylating agents in myeloid malignancies.Curr. Opin. Oncol.20(6) , 705–710 (2008).
  • Hollenbach PW , NguyenAN, BradyH et al.: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.PLoS One5(2) , E9001 (2010).
  • Muller A , FlorekM: 5-Azacytidine/Azacitidine.Recent Results Cancer Res.184 , 159–170 (2010).
  • Flotho C , ClausR, BatzC et al.: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.Leukemia23(6) , 1019–1028 (2009).
  • Robak T , KoryckaA, Lech-MarandaE, RobakP: Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Molecules14(3) , 1183–1226 (2009).
  • Bellezza I , TucciA, MinelliA: 2-Chloroadenosine and Human Prostate Cancer Cells.Anticancer Agents Med. Chem.8(7) , 783–789 (2008).
  • Hentosh P , PeffleyDM: The cladribine conundrum: deciphering the drug‘s mechanism of action.Expert Opin. Drug Metab. Toxicol.6(1) , 75–81 (2010).
  • Mori N , YokoojiT, KamioY, MurakamiT: Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats.Eur. J. Pharmacol.586(1–3) , 52–58 (2008).
  • Naka K , IkedaM, AbeK, DansakoH, KatoN: Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-a.Biochem. Biophys. Res. Commun.330(3) , 871–879 (2005).
  • Sahasranaman S , HowardD, RoyS: Clinical pharmacology and pharmacogenetics of thiopurines.Eur. J. Clin. Pharmacol.64(8) , 753–767 (2008).
  • Prefontaine E , MacdonaldJK, SutherlandLR: Azathioprine or 6-mercaptopurine for induction of remission in Crohn‘s disease.Cochrane Database Syst. Rev. (4) , CD000545 (2009).
  • Prefontaine E , SutherlandLR, MacdonaldJK, CepoiuM: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn‘s disease.Cochrane Database Syst. Rev. (1) , CD000067 (2009).
  • Shey M , KongnyuyEJ, ShangJ, WiysongeCS: A combination drug of abacavir–lamivudine–zidovudine (Trizivir) for treating HIV infection and aids.Cochrane Database Syst. Rev. (3) , CD005481 (2009).
  • Tozzi V : Pharmacogenetics of antiretrovirals.Antiviral Res.85(1) , 190–200 (2010).
  • Chien RN , LiawYF: Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.Best Pract. Res. Clin. Gastroenterol.22(6) , 1081–1092 (2008).
  • Achenbach CJ , ScarsiKK, MurphyRL: Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Adv. Ther.27(1) , 1–16 (2010).
  • Deval J : Antimicrobial strategies: inhibition of viral polymerases by 3´-hydroxyl nucleosides.Drugs69(2) , 151–166 (2009).
  • Vanpouille C , LiscoA, DerudasM et al.: A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.J. Infect Dis.201(4) , 635–643 (2010).
  • Sharma SD : Hepatitis C virus: molecular biology and current therapeutic options.Indian J. Med. Res.131 , 17–34 (2010).
  • Kimberlin DW , JacobsRF, WellerS et al.: Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.Clin. Infect Dis.50(2) , 221–228 (2010).
  • Jenh AM , ThioCL, PhamPA: Tenofovir for the treatment of hepatitis B virus.Pharmacotherapy29(10) , 1212–1227 (2009).
  • Cihlar T , LaflammeG, FisherR et al.: Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.Antimicrob. Agents Chemother.53(1) , 150–156 (2009).
  • Molina-Arcas M , Moreno-BuenoG, Cano-SoldadoP et al.: Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5´-DFUR in breast cancer MCF7 cells.Biochem. Pharmacol.72(12) , 1646–1656 (2006).
  • Smith KM , NgAM, YaoSY et al.: Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in xenopus oocytes.J. Physiol.558(Pt 3) , 807–823 (2004).
  • Clarke ML , DamarajuVL, ZhangJ et al.: The role of human nucleoside transporters in cellular uptake of 4´-thio-β-D-arabinofuranosylcytosine and β-D-arabinosylcytosine.Mol. Pharmacol.70(1) , 303–310 (2006).
  • Endo Y , ObataT, MurataD et al.: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides.Cancer Sci.98(10) , 1633–1637 (2007).
  • Rius M , StresemannC, KellerD et al.: Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation.Mol. Cancer Ther.8(1) , 225–231 (2009).
  • Huang Y , AnderleP, BusseyKJ et al.: Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.Cancer Res.64(12) , 4294–4301 (2004).
  • King KM , DamarajuVL, VickersMF et al.: A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.Mol. Pharmacol.69(1) , 346–353 (2006).
  • Molina-Arcas M , BellosilloB, CasadoFJ et al.: Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.Blood101(6) , 2328–2334 (2003).
  • Huang M , WangY, GuJ et al.: Determinants of sensitivity of human t-cell leukemia CCRF-CEM cells to immucillin-h.Leuk. Res.32(8) , 1268–1278 (2008).
  • Zhang J , TackaberryT, RitzelMW et al.: Cysteine-accessibility analysis of transmembrane domains 11–13 of human concentrative nucleoside transporter 3.Biochem. J.394(Pt 2) , 389–398 (2006).
  • Prus KL , AverettDR, ZimmermanTP: Transport and metabolism of 9-b-d-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx.Cancer Res.50(6) , 1817–1821 (1990).
  • Ishida K , TakaaiM, YotsutaniA, TaguchiM, HashimotoY: Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial ls180 cells.Biol. Pharm. Bull32(4) , 741–745 (2009).
  • Mori N , YokoojiT, KamioY, MurakamiT: Study on intestinal absorption sites of mizoribine and ribavirin, substrates for concentrative nucleoside transporter(s), in rats.Eur. J. Pharmacol.628(1–3) , 214–219 (2010).
  • Mori S , OhtsukiS, TakanagaH, KikkawaT, KangYS, TerasakiT: Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs.J. Neurochem90(4) , 931–941 (2004).
  • Yao SY , NgAM, SundaramM, CassCE, BaldwinSA, YoungJD: Transport of antiviral 3´-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in xenopus oocytes.Mol. Membr. Biol.18(2) , 161–167 (2001).
  • Jung N , LehmannC, RubbertA et al.: Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.Drug Metab. Dispos.36(8) , 1616–1623 (2008).
  • Jin MJ , HanHK: Interaction of zalcitabine with human organic anion transporter 1.Pharmazie61(5) , 491–492 (2006).
  • Truong DM , KalerG, KhandelwalA, SwaanPW, NigamSK: Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination.J. Biol. Chem.283(13) , 8654–8663 (2008).
  • Morita N , KusuharaH, SekineT, EndouH, SugiyamaY: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells.J. Pharmacol. Exp. Ther.298(3) , 1179–1184 (2001).
  • Li JY , BoadoRJ, PardridgeWM: Differential kinetics of transport of 2´,3´-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood–brain barrier.J. Pharmacol. Exp. Ther.299(2) , 735–740 (2001).
  • Wada S , TsudaM, SekineT et al.: Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.J. Pharmacol. Exp. Ther.294(3) , 844–849 (2000).
  • Govindarajan R , EndresCJ, WhittingtonD et al.: Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.Am. J. Physiol. Gastrointest. Liver Physiol.295(3) , G570–580 (2008).
  • Yamamoto T , SugawaraM, KikukawaT et al.: Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes.Biophys. Chem.147(1–2) , 59–65 (2010).
  • Sekine T , ChaSH, TsudaM et al.: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.FEBS Lett.429(2) , 179–182 (1998).
  • Friedrichsen GM , ChenW, BegtrupM, LeeCP, SmithPL, BorchardtRT: Synthesis of analogs of l-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells.Eur. J. Pharm. Sci.16(1–2) , 1–13 (2002).
  • Uwai Y , IdaH, TsujiY, KatsuraT, InuiK: Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).Pharm. Res.24(4) , 811–815 (2007).
  • Mahony WB , DominBA, DalugeSM, ZimmermanTP: Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir.Biochem. Pharmacol.68(9) , 1797–1805 (2004).
  • Xu AS , ChuCK, LondonRE: 19F NMR study of the uptake of 2´-fluoro-5-methyl-β-l-arabinofuranosyluracil in erythrocytes: evidence of transport by facilitated and nonfacilitated pathways.Biochem. Pharmacol.55(10) , 1611–1619 (1998).
  • Brandl M , WuX, HolperM et al.: Physicochemical properties of the nucleoside prodrug r1626 leading to high oral bioavailability.Drug Dev. Ind. Pharm.34(7) , 683–691 (2008).
  • Guo Y , KotovaE, ChenZS et al.: MRP8, ATP-binding cassette C11 (ABCC1 1), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2´,3´-dideoxycytidine and 9´-(2´-phosphonylmethoxyethyl)adenine.J. Biol. Chem.278(32) , 29509–29514 (2003).
  • Zeng H , LinZP, SartorelliAC: Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line l1210/vMDRc.06.Biochem. Pharmacol.68(5) , 911–921 (2004).
  • Oguri T , BesshoY, AchiwaH et al.: MRP8/ABCC11 directly confers resistance to 5-fluorouracil.Mol. Cancer Ther.6(1) , 122–127 (2007).
  • Pratt S , ShepardRL, KandasamyRA, JohnstonPA, PerryW, 3rd, Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer Ther.4(5) , 855–863 (2005).
  • Guo Y , KockK, RitterCA et al.: Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.Clin. Cancer Res.15(5) , 1762–1769 (2009).
  • Ritter CA , JedlitschkyG, Meyer Zu Schwabedissen H, Grube M, Kock K, Kroemer HK: Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev.37(1) , 253–278 (2005).
  • Oguri T , AchiwaH, SatoS et al.: The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.Mol. Cancer Ther.5(7) , 1800–1806 (2006).
  • De Wolf C , JansenR, YamaguchiH et al.: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.Mol. Cancer Ther.7(9) , 3092–3102 (2008).
  • Reid G , WielingaP, ZelcerN et al.: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.Mol. Pharmacol.63(5) , 1094–1103 (2003).
  • Eilers M , RoyU, MondalD: MRP (ABCc) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.Exp. Biol. Med. (Maywood)233(9) , 1149–1160 (2008).
  • Wang X , BabaM: The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.Antivir. Chem. Chemother.16(4) , 213–216 (2005).
  • Janneh O , OwenA, BrayPG, BackDJ, PirmohamedM: The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.Br. J. Pharmacol.159(2) , 484–493 (2010).
  • Wang X , FurukawaT, NitandaT et al.: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.Mol. Pharmacol.63(1) , 65–72 (2003).
  • Kim HS , SunwooYE, RyuJY et al.: The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine.Br. J. Clin. Pharmacol.64(5) , 645–654 (2007).
  • Karla PK , QuinnTL, HerndonBL, ThomasP, PalD, MitraA: Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux.J. Ocul Pharmacol. Ther.25(2) , 121–132 (2009).
  • Wijnholds J , MolCA, Van Deemter L et al.: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl Acad. Sci. USA97(13) , 7476–7481 (2000).
  • Ming X , ThakkerDR: Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil.Biochem. Pharmacol.79(3) , 455–462 (2010).
  • Brody SR , HumphreysMH, GambertoglioJG, SchoenfeldP, CundyKC, AweekaFT: Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.Clin. Pharmacol. Ther.65(1) , 21–28 (1999).
  • Imaoka T , KusuharaH, AdachiM, SchuetzJD, TakeuchiK, SugiyamaY: Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.Mol. Pharmacol.71(2) , 619–627 (2007).
  • Shaik N , GiriN, PanG, ElmquistWF: P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.Drug Metab. Dispos.35(11) , 2076–2085 (2007).
  • Pan G , GiriN, ElmquistWF: ABCG2 BCRP1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.Drug Metab. Dispos.35(7) , 1165–1173 (2007).
  • Ngo LY , PatilSD, UnadkatJD: Ontogenic and longitudinal activity of Na+-nucleoside transporters in the human intestine.Am. J. Physiol. Gastrointest. Liver Physiol.280(3) , G475–G481 (2001).
  • Govindarajan R , BakkenAH, HudkinsKL et al.: In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.Am. J. Physiol. Regul. Integr. Comp. Physiol.293(5) , R1809–R1822 (2007).
  • Damaraju VL , ElwiAN, HunterC et al.: Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.Am. J. Physiol. Renal Physiol.293(1) , F200–F211 (2007).
  • Koehler MR , WissingerB, GorboulevV, KoepsellH, SchmidM: The two human organic cation transporter genes SLC22A1 and SLC22A 2 are located on chromosome 6q26.Cytogenet. Cell Genet.79(3–4) , 198–200 (1997).
  • Lips KS , VolkC, SchmittBM et al.: Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium.Am. J. Respir Cell Mol. Biol.33(1) , 79–88 (2005).
  • Wessler I , RothE, DeutschC et al.: Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters.Br. J. Pharmacol.134(5) , 951–956 (2001).
  • Motohashi H , SakuraiY, SaitoH et al.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney.J. Am. Soc. Nephrol.13(4) , 866–874 (2002).
  • Busch AE , KarbachU, MiskaD et al.: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.Mol. Pharmacol.54(2) , 342–352 (1998).
  • Muller J , LipsKS, MetznerL, NeubertRH, KoepsellH, BrandschM: Drug specificity and intestinal membrane localization of human organic cation transporters (OCT).Biochem. Pharmacol.70(12) , 1851–1860 (2005).
  • Sata R , OhtaniH, TsujimotoM et al.: Functional analysis of organic cation transporter 3 expressed in human placenta.J. Pharmacol. Exp. Ther.315(2) , 888–895 (2005).
  • Shang T , UihleinAV, Van Asten J, Kalyanaraman B, Hillard CJ: 1-methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J. Neurochem85(2) , 358–367 (2003).
  • Alebouyeh M , TakedaM, OnozatoML et al.: Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites.J. Pharmacol. Sci.93(4) , 430–436 (2003).
  • Enomoto A , TakedaM, ShimodaM et al.: Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors.J. Pharmacol. Exp. Ther.301(3) , 797–802 (2002).
  • Simonson GD , VincentAC, RobergKJ, HuangY, IwanijV: Molecular cloning and characterization of a novel liver-specific transport protein.J. Cell Sci.107(Pt 4) , 1065–1072 (1994).
  • Walker D , ThwaitesDT, SimmonsNL, GilbertHJ, HirstBH: Substrate upregulation of the human small intestinal peptide transporter, hPepT1.J. Physiol.507(Pt 3) , 697–706 (1998).
  • Thiebaut F , TsuruoT, HamadaH, GottesmanMM, PastanI, WillinghamMC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc. Natl Acad. Sci. USA84(21) , 7735–7738 (1987).
  • Sugawara I , KataokaI, MorishitaY et al.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.Cancer Res.48(7) , 1926–1929 (1988).
  • Cordon-Cardo C , O‘BrienJP, CasalsD et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites.Proc. Natl Acad. Sci. USA86(2) , 695–698 (1989).
  • Ceckova-Novotna M , PavekP, StaudF: P-glycoprotein in the placenta: expression, localization, regulation and function.Reprod. Toxicol.22(3) , 400–410 (2006).
  • Hemauer SJ , NanovskayaTN, Abdel-RahmanSZ, PatrikeevaSL, HankinsGD, AhmedMS: Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms.Biochem. Pharmacol.79(6) , 921–925 (2010).
  • Bellusci CP , RoccoCA, AulicinoPC et al.: MDR1 3435T and 1236T alleles delay disease progression to pediatric aids but have no effect on HIV-1 vertical transmission.AIDS24(6) , 833–840 (2010).
  • Yang YL , LinDT, ChangSK et al.: Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia.Pediatr. Blood Cancer54(2) , 206–211 (2010).
  • Khedri A , Nejat-ShokouhiA, SalekR et al.: Association of the colorectal cancer and MDR1 gene polymorphism in an iranian population.Mol. Biol. Rep. DOI: 10.1007/s11033-010-9957-9 (2010) (Epub ahead of print).
  • Rabascio C , LaszloD, AndreolaG et al.: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström‘s macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2´-deoxyadenosine (2-CDA) and rituximab.Leuk. Res.34(4) , 454–457 (2010).
  • Mackey JR , GalmariniCM, GrahamKA et al.: Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.Blood105(2) , 767–774 (2005).
  • Tsang RY , SantosC, GhoshS et al.: Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.Mod. Pathol.21(11) , 1387–1393 (2008).
  • Lai R , BartlettNL, MackeyJR et al.: High expression of nucleoside transporter protein hENT1 in reed-sternberg cells is associated with treatment failure in relapsed/refractory hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin – a CALGB 59804 correlative study.Leuk. Lymphoma49(6) , 1202–1205 (2008).
  • Al-Massaeid AL , CraikJD: Decreased nucleoside transport and hENT1 transporter expression in b-thalassemia major.Med. Princ. Pract.18(3) , 180–186 (2009).
  • Santini D , VincenziB, FrattoME et al.: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.J. Cell Physiol.223(2) , 384–388 (2010).
  • Hallermann C , NiermannC, FischerRJ, SchulzeHJ: New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.J. Am. Acad. Dermatol.56(4) , 588–597 (2007).
  • Yokoo S , MasudaS, YonezawaA, TeradaT, KatsuraT, InuiK: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.Drug Metab. Dispos.36(11) , 2299–2306 (2008).
  • Damiani D , TiribelliM, MicheluttiA et al.: Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.Leuk. Res. DOI:10.1016/j.leukres.2010.01.008 (2010) (Epub ahead of print).
  • Meuwis MA , FilletM, GeurtsP et al.: Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.Biochem. Pharmacol.73(9) , 1422–1433 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.